Want to see AU:CYC full AI Analyst Report?
CYC Stock Chart & Stats
AU$0.52
-AU$0.02(-3.57%)
At close: 4:00 PM EDT
AU$0.52
-AU$0.02(-3.57%)
Day’s Range― - ―
52-Week RangeAU$0.45 - AU$1.29
Previous CloseN/A
Volume5.87K
Average Volume (3M)47.12K
Market Cap
AU$56.58M
Enterprise ValueAU$51.92
Total Cash (Recent Filing)AU$12.25M
Total Debt (Recent Filing)AU$7.80M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Feb 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.64%
Share Statistics
EPS (TTM)-0.16
Shares Outstanding125,734,146
10 Day Avg. Volume42,817
30 Day Avg. Volume47,116
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)3.98
Price to Sales (P/S)3.34
P/FCF Ratio-5.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside92.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.15
Revenue Forecast (FY)AU$36.60M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables And Installed BaseTechnegas consumables generate repeat sales from the installed generator base, so revenue is not solely dependent on one-time equipment placements. As hospitals and imaging providers continue using existing systems, recurring utilisation can support customer retention and provide a foundation for expansion.
Sustained Revenue GrowthRevenue increased steadily from 2020 to 2025, with approximately 8.5% year-on-year growth in 2025. That sustained top-line progression indicates improving commercial traction and gives the company a platform to scale its installed base and recurring consumables business.
Meaningful Equity Base2025 equity of approximately $27.1 million provides a meaningful capital buffer against ongoing losses. Although leverage is rising, this equity base can help absorb near-term volatility and gives Cyclopharm some financial capacity while it works to improve operating performance.
Bears Say
Severe Profitability DeteriorationProfitability has deteriorated despite revenue growth: Cyclopharm remained deeply loss-making, and gross profit turned negative in 2025, meaning reported costs exceeded revenue. This weak margin profile threatens earnings durability and requires a substantial operational turnaround before growth can produce sustainable profits.
Persistent Cash BurnOperating cash flow was negative in every year and worsened to about negative $17.3 million in 2025; free cash flow was about negative $19.3 million. Persistent absolute cash burn implies continuing funding needs and limits the company's ability to self-finance growth.
Rising Leverage And Balance-sheet PressureTotal debt rose materially to approximately $14.9 million in 2025 from $8.3 million in 2024, while equity and total assets declined. This combination increases financial risk, reduces balance-sheet flexibility, and can constrain investment in expansion while losses continue.
Cyclopharm Limited News
CYC FAQ
What was Cyclopharm Limited’s price range in the past 12 months?
Cyclopharm Limited lowest share price was AU$0.45 and its highest was AU$1.29 in the past 12 months.
What is Cyclopharm Limited’s market cap?
Cyclopharm Limited’s market cap is AU$56.58M.
When is Cyclopharm Limited’s upcoming earnings report date?
Cyclopharm Limited’s upcoming earnings report date is Feb 24, 2027 which is in 148 days.
How were Cyclopharm Limited’s earnings last quarter?
Cyclopharm Limited released its earnings results on Aug 23, 2026. The company reported -AU$0.073 earnings per share for the quarter.
Is Cyclopharm Limited overvalued?
According to Wall Street analysts Cyclopharm Limited’s price is currently Undervalued.
Does Cyclopharm Limited pay dividends?
Cyclopharm Limited pays a Semiannually dividend of AU$0.008 which represents an annual dividend yield of 0.64%. See more information on Cyclopharm Limited dividends here
What is Cyclopharm Limited’s EPS estimate?
Cyclopharm Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyclopharm Limited have?
Cyclopharm Limited has 125,734,146 shares outstanding.
What happened to Cyclopharm Limited’s price movement after its last earnings report?
Cyclopharm Limited reported an EPS of -AU$0.073 in its last earnings report. Following the earnings report the stock price went down -1.765%.
Which hedge fund is a major shareholder of Cyclopharm Limited?
Currently, no hedge funds are holding shares in AU:CYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cyclopharm Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.00 (92.31% Upside)
AU$1.00 (92.31% Upside)
Blogger Sentiment
Bullish
AU:CYC Sentiment 71%
Sector Average 64%
Sector Average 64%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.15%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cyclopharm Limited
Cyclopharm Limited is an international enterprise specializing in the production and global distribution of medical devices and radiopharmaceuticals, with operations spanning Asia Pacific, Europe, Canada, and other regions. The company's business activities are structured into two principal divisions: Technegas and Molecular Imaging. Through its Technegas segment, Cyclopharm supplies diagnostic apparatus and accompanying consumables critical for clinicians in the identification of pulmonary embolisms, alongside distributing third-party offerings to the broader diagnostic imaging sector. Conversely, the Molecular Imaging division provides advanced radiopharmaceutical agents essential for medical practitioners diagnosing conditions such as cancer, various neurological disorders, and cardiac diseases. Cyclopharm primarily serves nuclear medicine departments. Established in 1986, the company's corporate headquarters are located in Kingsgrove, Australia.
CYC Stock 12 Month Forecast
Average Price Target
AU$1.00
▲(92.31% Upside)
Technical Analysis
Compumedics Limited
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―
OncoSil Medical Ltd
―
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―